A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib

Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 Malumbres, 2014, Cyclin-dependent kinases, Genome Biol., 15, 122, 10.1186/gb4184 Otto, 2017, Cell cycle proteins as promising targets in cancer therapy, Nat. Rev. Cancer, 17, 93, 10.1038/nrc.2016.138 Asghar, 2015, The history and future of targeting cyclin-dependent kinases in cancer therapy, Nat. Rev. Drug Discov., 14, 130, 10.1038/nrd4504 Sherr, 1999, CDK inhibitors: positive and negative regulators of G1-phase progression, Genes Dev., 13, 1501, 10.1101/gad.13.12.1501 VanArsdale, 2015, Molecular pathways: targeting the cyclin D-CDK4/6 axis for cancer treatment, Clin. Cancer Res., 21, 2905, 10.1158/1078-0432.CCR-14-0816 Ingham, 2017, Cell-cycle therapeutics come of age, J. Clin. Oncol., 35, 2949, 10.1200/JCO.2016.69.0032 Sobhani, 2019, Updates on the CDK4/6 inhibitory strategy and combinations in breast cancer, Cells, 8, 10.3390/cells8040321 Burkhart, 2008, Cellular mechanisms of tumour suppression by the retinoblastoma gene, Nat. Rev. Cancer, 8, 671, 10.1038/nrc2399 Du, 2009, The Rb pathway and cancer therapeutics, Curr. Drug Targets, 10, 581, 10.2174/138945009788680392 Knudsen, 2010, Targeting the RB-pathway in cancer therapy, Clin. Cancer Res., 16, 1094, 10.1158/1078-0432.CCR-09-0787 O’Leary, 2016, Treating cancer with selective CDK4/6 inhibitors, Nat. Rev. Clin. Oncol., 13, 417, 10.1038/nrclinonc.2016.26 Hamilton, 2016, Targeting CDK4/6 in patients with cancer, Cancer Treat. Rev., 45, 129, 10.1016/j.ctrv.2016.03.002 Klein, 2018, C.D.K.4/6 inhibitors: the mechanism of action may not be as simple as once thought, Cancer Cell, 34, 9, 10.1016/j.ccell.2018.03.023 Sherr, 2016, Targeting CDK4 and CDK6: from discovery to therapy, Cancer Discov., 6, 353, 10.1158/2159-8290.CD-15-0894 Goetz, 2017, MONARCH 3: abemaciclib as initial therapy for advanced breast cancer, J. Clin. Oncol., 35, 3638, 10.1200/JCO.2017.75.6155 Sledge, 2017, MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy, J. Clin. Oncol., 35, 2875, 10.1200/JCO.2017.73.7585 Dickler, 2017, A phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR(+)/HER2(−) metastatic breast cancer, Clin. Cancer Res., 23, 5218, 10.1158/1078-0432.CCR-17-0754 Lee, 2019, Abemaciclib, a potent cyclin-dependent kinase 4 and 6 inhibitor, for treatment of ER-positive metastatic breast cancer, Future Oncol., 10.2217/fon-2019-0169 Marra, 2019, Are all cyclin-dependent kinases 4/6 inhibitors created equal?, NPJ Breast Cancer, 5, 27, 10.1038/s41523-019-0121-y Vidula, 2016, Cyclin-dependent kinase 4/6 inhibitors for the treatment of breast cancer: a review of preclinical and clinical data, Clin. Breast Cancer, 16, 8, 10.1016/j.clbc.2015.07.005 Hu, 2009, A requirement for cyclin-dependent kinase 6 in thymocyte development and tumorigenesis, Cancer Res., 69, 810, 10.1158/0008-5472.CAN-08-2473 Hu, 2011, CDK6 kinase activity is required for thymocyte development, Blood, 117, 6120, 10.1182/blood-2010-08-300517 Patnaik, 2016, Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors, Cancer Discov., 6, 740, 10.1158/2159-8290.CD-16-0095 Poratti, 2019, Third-generation CDK inhibitors: a review on the synthesis and binding modes of palbociclib, ribociclib and abemaciclib, Eur. J. Med. Chem., 172, 143, 10.1016/j.ejmech.2019.03.064 Kim, 2018, The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models, Oncotarget, 9, 35226, 10.18632/oncotarget.26215 Gelbert, 2014, Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine, Invest. New Drugs, 32, 825, 10.1007/s10637-014-0120-7 Knudsen, 2017, Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature, Oncotarget, 8, 43678, 10.18632/oncotarget.18435 Roskoski, 2019, Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs, Pharmacol. Res., 139, 471, 10.1016/j.phrs.2018.11.035 Hafner, 2019, Multiomics profiling establishes the polypharmacology of FDA-approved CDK4/6 inhibitors and the potential for differential clinical activity, Cell Chem. Biol., 26, 1067, 10.1016/j.chembiol.2019.05.005 Chen, 2016, Spectrum and degree of CDK drug interactions predicts clinical performance, Mol. Cancer Ther., 15, 2273, 10.1158/1535-7163.MCT-16-0300 Schettini, 2018, CDK 4/6 inhibitors as single agent in advanced solid tumors, Front. Oncol., 8, 608, 10.3389/fonc.2018.00608 Puyol, 2010, A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma, Cancer Cell, 18, 63, 10.1016/j.ccr.2010.05.025 Goldman, 2018, A randomized phase 3 study of abemaciclib versus erlotinib in previously treated patients with stage IV NSCLC with KRAS mutation: JUNIPER, J. Clin. Oncol., 36, 10.1200/JCO.2018.36.15_suppl.9025 Goldman, 2016, Clin. Lung Cancer, 17, 80, 10.1016/j.cllc.2015.08.003 Torres-Guzmán, 2017, Preclinical characterization of abemaciclib in hormone receptor positive breast cancer, Oncotarget, 8, 69493, 10.18632/oncotarget.17778 DeMichele, 2015, CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment, Clin. Cancer Res., 21, 995, 10.1158/1078-0432.CCR-14-2258 Dickler, 2016, MONARCH1: results from a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for advanced disease, J. Clin. Oncol., 34, 10.1200/JCO.2016.34.15_suppl.510 Martin, 2018 Finn, 2016, Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers, Breast Cancer Res., 18, 17, 10.1186/s13058-015-0661-5 O’Brien, 2018, Preclinical activity of abemaciclib alone or in combination with antimitotic and targeted therapies in breast Cancer, Mol. Cancer Ther., 17, 897, 10.1158/1535-7163.MCT-17-0290 Roman, 2018, KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target, Mol. Cancer, 17, 33, 10.1186/s12943-018-0789-x Scagliotti, 2018 The Cancer Genome Atlas Research Network, 2008, Comprehensive genomic characterization defines human glioblastoma genes and core pathways, Nature, 455, 1061, 10.1038/nature07385 Raub, 2015, Brain exposure of two selective dual CDK4 and CDK6 inhibitors and the antitumor activity of CDK4 and CDK6 inhibition in combination with temozolomide in an intracranial glioblastoma xenograft, Drug Metab. Dispos., 43, 1360, 10.1124/dmd.114.062745 Barnholtz-Sloan, 2004, Incidence proportions of brain metastases in patients diagnosed (1973–2001) in the Metropolitan detroit cancer surveillance system, J. Clin. Oncol., 22, 2865, 10.1200/JCO.2004.12.149 Karamboulas, 2018, Patient-derived xenografts for prognostication and personalized treatment for head and neck squamous cell carcinoma, Cell Rep., 25, 1318, 10.1016/j.celrep.2018.10.004 Kosovec, 2017, CDK4/6 dual inhibitor abemaciclib demonstrates compelling preclinical activity against esophageal adenocarcinoma: a novel therapeutic option for a deadly disease, Oncotarget, 8, 100421, 10.18632/oncotarget.22244 Dempsey, 2013 Iriyama, 2018, The cyclin-dependent kinase 4/6 inhibitor, abemaciclib, exerts dose-dependent cytostatic and cytocidal effects and induces autophagy in multiple myeloma cells, Leuk. Lymphoma, 59, 1439, 10.1080/10428194.2017.1376741 de Groot, 2017, CDK4/6 inhibition in early and metastatic breast cancer: a review, Cancer Treat. Rev., 60, 130, 10.1016/j.ctrv.2017.09.003 Zwijsen, 1997, CDK-independent activation of estrogen receptor by cyclin D1, Cell, 88, 405, 10.1016/S0092-8674(00)81879-6 George, 2017, MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapy, J. Clin. Oncol., 35, 2875, 10.1200/JCO.2017.73.7585 Goetz, 2017, MONARCH 3: abemaciclib as initial therapy for advanced breast cancer, J. Clin. Oncol., 35, 3638, 10.1200/JCO.2017.75.6155 Johnston, 2019, MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer, NPJ Breast Cancer, 5, 5, 10.1038/s41523-018-0097-z van Ommen-Nijhof, 2018, Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial, BMC Cancer, 18, 1146, 10.1186/s12885-018-4978-1 Robertson, 2016, Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial, Lancet, 388, 2997, 10.1016/S0140-6736(16)32389-3 Rossi, 2019, Should all patients with HR-positive HER2-negative metastatic breast cancer receive CDK 4/6 inhibitor as first-line based therapy? A network meta-analysis of data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT trials, Cancers (Basel), 11, 10.3390/cancers11111661 Petrelli, 2019, Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials, Breast Cancer Res. Treat., 174, 597, 10.1007/s10549-019-05133-y Yu, 2006, Requirement for CDK4 kinase function in breast cancer, Cancer Cell, 9, 23, 10.1016/j.ccr.2005.12.012 Goel, 2016, Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4/6 inhibitors, Cancer Cell, 29, 255, 10.1016/j.ccell.2016.02.006 Malumbres, 2016, CDK4/6 inhibitors resTORe therapeutic sensitivity in HER(2)(+) breast cancer, Cancer Cell, 29, 243, 10.1016/j.ccell.2016.02.016 Adkins, 2019, Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial, Lancet Oncol., 20, 1295, 10.1016/S1470-2045(19)30405-X Teh, 2019, Arrested developments: CDK4/6 inhibitor resistance and alterations in the tumor immune microenvironment, Clin. Cancer Res., 25, 921, 10.1158/1078-0432.CCR-18-1967 Zhang, 2018, Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance, Nature, 553, 91, 10.1038/nature25015 Goel, 2017, CDK4/6 inhibition triggers anti-tumour immunity, Nature, 548, 471, 10.1038/nature23465 Deng, 2018, CDK4/6 inhibition augments antitumor immunity by enhancing T-cell activation, Cancer Discov., 8, 216, 10.1158/2159-8290.CD-17-0915 Schaer, 2018, The CDK4/6 inhibitor abemaciclib induces a T cell inflamed tumor microenvironment and enhances the efficacy of PD-L1 checkpoint blockade, Cell Rep., 22, 2978, 10.1016/j.celrep.2018.02.053 Dempsey, 2017, The cdk4/6 inhibitor abemaciclib induces synergistic immune activation and antitumor efficacy in combination with pd-l1 blockade, AACR Mazieres, 2017, P2.06-012 phase 2 study of abemaciclib + pembrolizumab in KRAS mutation, PD-L1+, stage IV non-small cell or squamous cell lung cancer: topic: phase II + NK, J. Thorac. Oncol., 12, S1076, 10.1016/j.jtho.2016.11.1505 Gopalan, 2018, CDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is synergistic with mTOR inhibition, Oncotarget, 9, 37352, 10.18632/oncotarget.26424 Knudsen, 2017, The strange case of CDK4/6 inhibitors: mechanisms, resistance, and combination strategies, Trends Cancer, 3, 39, 10.1016/j.trecan.2016.11.006 Ku, 2016, The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma, Oncotarget, 7, 14803, 10.18632/oncotarget.7543 O’Shaughnessy, 2018, Everolimus-based combination therapies for HR+, HER2− metastatic breast cancer, Cancer Treat. Rev., 69, 204, 10.1016/j.ctrv.2018.07.013 Tolaney, 2015, A phase Ib study of abemaciclib with therapies for metastatic breast cancer, J. Clin. Oncol., 33 Kim, 2015, A phase Ib study of abemaciclib in combination with multiple single agents in stage IV NSCLC, J. Clin. Oncol., 33, 10.1200/jco.2015.33.15_suppl.8047 Sanz-Garcia, 2017, BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives, Ann. Oncol., 28, 2648, 10.1093/annonc/mdx401 Wu, 2017 Yadav, 2015, Co-targeting BRAF and cyclin dependent kinases 4/6 for BRAF mutant cancers, Pharmacol. Ther., 149, 139, 10.1016/j.pharmthera.2014.12.003 Chen, 2017, RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1, Oncogene, 37, 821, 10.1038/onc.2017.384 Patel, 2003, Plasma and cerebrospinal fluid pharmacokinetics of temozolomide, J. Neuro-Oncol., 61, 203, 10.1023/A:1022592913323 Newlands, 1997, Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials, Cancer Treat. Rev., 23, 35, 10.1016/S0305-7372(97)90019-0 Cohen, 2005, Food and drug administration drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme, Clin. Cancer Res., 11, 6767, 10.1158/1078-0432.CCR-05-0722 Raub, 2015, Brain exposure of two selective dual CDK4 and CDK6 inhibitors and the antitumor activity of CDK4 and CDK6 inhibition in combination with temozolomide in an intracranial glioblastoma xenograft, Drug Metab. Dispos., 43, 1360, 10.1124/dmd.114.062745 Adhikari, 2019, Abstract 3884: advancing glioblastoma drug regimen development to support combination therapy through integrated PKPD modeling and simulation-based predictions, Cancer Res., 79, 10.1158/1538-7445.AM2019-3884 Alexander, 2017, Individualized screening trial of innovative glioblastoma therapy (INSIGhT), J. Clin. Oncol., 35, 10.1200/JCO.2017.35.15_suppl.TPS2079 Zatyka, 2002, Identification of cyclin D1 and other novel targets for the Von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in Von Hippel-Lindau disease, Cancer Res., 62, 3803 Logan, 2013, PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity, Anticancer Res., 33, 2997 Mahalingam, 2011, Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma, Br. J. Cancer, 105, 1563, 10.1038/bjc.2011.426 Small, 2017, The addition of abemaciclib to sunitinib induces regression of renal cell carcinoma xenograft tumors, Oncotarget, 8, 95116, 10.18632/oncotarget.19618 Naz, 2019, Abemaciclib: a multi-functional radiation modifier, Oncotarget, 10, 1230, 10.18632/oncotarget.26652 Naz, 2018, Abemaciclib, a selective CDK4/6 inhibitor, enhances the radiosensitivity of non–small cell lung cancer in vitro and in vivo, Clin. Cancer Res., 24, 3994, 10.1158/1078-0432.CCR-17-3575 Figura, 2019, CDK 4/6 inhibitors and stereotactic radiation in the management of hormone receptor positive breast cancer brain metastases, J. Neurooncol., 144, 583, 10.1007/s11060-019-03260-6 Baughn, 2006, A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6, Cancer Res., 66, 7661, 10.1158/0008-5472.CAN-06-1098 Menu, 2008, A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model, Cancer Res., 68, 5519, 10.1158/0008-5472.CAN-07-6404 Joshi, 2009, Notch signaling mediates G1/S cell-cycle progression in T cells via cyclin D3 and its dependent kinases, Blood, 113, 1689, 10.1182/blood-2008-03-147967 Rao, 2009, Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells, Cancer Res., 69, 3060, 10.1158/0008-5472.CAN-08-4295 Pernas, 2018, CDK4/6 inhibition in breast cancer: current practice and future directions, Ther. Adv. Med. Oncol., 10, 10.1177/1758835918786451 Preusser, 2018, CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion, ESMO Open, 3, 10.1136/esmoopen-2018-000368 Schoninger, 2020, The ongoing search for biomarkers of CDK4/6 inhibitor responsiveness in breast cancer, Mol. Cancer Ther., 19, 3, 10.1158/1535-7163.MCT-19-0253 Duso, 2019, An analysis of available biomarker data for targeting cyclin-dependent kinases 4 and 6 (CDK4/6) in breast cancer, Expert Rev. Precis. Med. Drug Dev., 4, 129, 10.1080/23808993.2019.1604136 Tolaney, 2016, Biomarkers exploratory biomarkers in MONARCH 1, a phase II study of abemaciclib monotherapy in hormone-receptor positive (HR) HER2-metastatic breast cancer (MBC), Ann. Oncol., 27, 10.1093/annonc/mdw435.01 Gong, 2017, Genomic aberrations that activate D-type cyclins are associated with enhanced sensitivity to the CDK4 and CDK6 inhibitor abemaciclib, Cancer Cell, 32, 761, 10.1016/j.ccell.2017.11.006 Shapiro, 2017, Genomic biomarkers predicting response to selective CDK4/6 inhibition: progress in an elusive search, Cancer Cell, 32, 721, 10.1016/j.ccell.2017.11.013 Yang, 2017, Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence, Oncogene, 36, 2255, 10.1038/onc.2016.379 Li, 2018, Loss of the FAT1 tumor suppressor promotes resistance to CDK4/6 inhibitors via the hippo pathway, Cancer Cell, 34, 893, 10.1016/j.ccell.2018.11.006 Spring, 2017 Chen, 2019, Latest overview of the cyclin-dependent kinases 4/6 inhibitors in breast cancer: the past, the present and the future, J. Cancer, 10, 6608, 10.7150/jca.33079 Mullins, 2018 Small, 2015, Abstract 5323: Targeting PIM1 and CDK4/6 Kinases in Renal Cell Carcinoma, AACR, Cancer Res., 75 Nicholson, 2019, Loss of CDK4/6 Activity Is Synthetic Lethal with VHL Inactivation in Clear Cell Renal Cell Carcinoma, FASEB J., 33 Allison, 2020, Synthetic lethality between loss of CDK4/6 activity and VHL inactivation, Nat. Rev. Nephrol., 16 Bhagwat, 2020, ERK inhibitor LY3214996 targets ERK pathway–driven cancers: A therapeutic approach toward precision medicine, Mol. Cancer Ther., 19, 325, 10.1158/1535-7163.MCT-19-0183